|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1177.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 21.00 | 24.83 | 53.13 | 32.03 | 26.11 | CEPS(Rs) | 28.43 | 31.92 | 61.46 | 40.11 | 33.16 | DPS(Rs) | 3.00 | 9.00 | 4.00 | 3.00 | 2.50 | Book NAV/Share(Rs) | 305.75 | 292.15 | 271.80 | 222.78 | 193.73 | Tax Rate(%) | 23.78 | 11.16 | 25.76 | 20.81 | 22.14 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 13.43 | 12.82 | 25.95 | 20.11 | 19.56 | EBIT Margin(%) | 13.42 | 14.58 | 26.59 | 19.48 | 17.83 | Pre Tax Margin(%) | 12.53 | 14.43 | 26.41 | 17.67 | 15.95 | PAT Margin (%) | 9.55 | 12.82 | 19.61 | 13.99 | 12.42 | Cash Profit Margin (%) | 12.93 | 16.48 | 22.68 | 17.52 | 15.78 | Performance Ratios | | | | | | ROA(%) | 4.57 | 5.82 | 14.26 | 9.96 | 9.02 | ROE(%) | 7.02 | 8.81 | 21.49 | 15.38 | 14.34 | ROCE(%) | 8.44 | 8.52 | 23.03 | 16.01 | 14.85 | Asset Turnover(x) | 0.48 | 0.45 | 0.73 | 0.71 | 0.73 | Sales/Fixed Asset(x) | 2.16 | 1.83 | 2.47 | 2.31 | 2.53 | Working Capital/Sales(x) | 4.22 | 2.01 | 2.85 | 2.73 | 3.35 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.46 | 0.55 | 0.41 | 0.43 | 0.40 | Receivable days | 120.87 | 159.20 | 134.65 | 149.89 | 143.76 | Inventory Days | 105.97 | 131.81 | 105.77 | 113.34 | 109.38 | Payable days | 113.35 | 128.68 | 113.22 | 118.72 | 115.57 | Valuation Parameters | | | | | | PER(x) | 24.67 | 26.94 | 16.59 | 12.89 | 30.10 | PCE(x) | 18.22 | 20.96 | 14.34 | 10.30 | 23.70 | Price/Book(x) | 1.69 | 2.29 | 3.24 | 1.85 | 4.06 | Yield(%) | 0.58 | 1.35 | 0.45 | 0.73 | 0.32 | EV/Net Sales(x) | 2.69 | 3.63 | 3.49 | 2.08 | 4.12 | EV/Core EBITDA(x) | 15.87 | 19.10 | 11.72 | 9.02 | 19.36 | EV/EBIT(x) | 19.87 | 24.76 | 13.08 | 10.65 | 23.00 | EV/CE(x) | 1.23 | 1.58 | 2.29 | 1.42 | 3.18 | M Cap / Sales | 2.37 | 3.47 | 3.26 | 1.81 | 3.76 | Growth Ratio | | | | | | Net Sales Growth(%) | 13.33 | -28.67 | 18.35 | 9.08 | 19.36 | Core EBITDA Growth(%) | 0.95 | -54.47 | 52.58 | 18.33 | -5.17 | EBIT Growth(%) | 4.53 | -60.81 | 61.54 | 19.03 | -8.36 | PAT Growth(%) | -15.42 | -53.27 | 65.86 | 22.69 | -15.61 | EPS Growth(%) | -15.42 | -53.27 | 65.86 | 22.69 | -15.61 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.23 | 0.11 | 0.25 | 0.29 | 0.40 | Current Ratio(x) | 1.44 | 2.35 | 1.83 | 1.77 | 1.55 | Quick Ratio(x) | 0.85 | 1.55 | 1.11 | 1.09 | 0.96 | Interest Cover(x) | 15.04 | 97.66 | 147.20 | 10.74 | 9.51 | Total Debt/Mcap(x) | 0.14 | 0.05 | 0.08 | 0.15 | 0.10 |
|
|
|
|
|
|